Literature DB >> 18781671

The history of dopamine and levodopa in the treatment of Parkinson's disease.

Stanley Fahn1.   

Abstract

The discoveries of dopamine as a neurotransmitter in the brain, its depletion in patients with Parkinson disease, and its replacement with levodopa therapy were major revolutionary events in the rise to effective therapy for patients with this disorder. This review describes these events and the persons who carried out these accomplishments. Their impact went beyond a single clinical entity of parkinsonism, for it opened up the beginning of a much better understanding of the role of dopamine in other neurologic movement disorders and also in many psychiatric diseases. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781671     DOI: 10.1002/mds.22028

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  53 in total

1.  Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.

Authors:  Carrie K Jones; Darren W Engers; Analisa D Thompson; Julie R Field; Anna L Blobaum; Stacey R Lindsley; Ya Zhou; Rocco D Gogliotti; Satyawan Jadhav; Rocio Zamorano; Jim Bogenpohl; Yoland Smith; Ryan Morrison; J Scott Daniels; C David Weaver; P Jeffrey Conn; Craig W Lindsley; Colleen M Niswender; Corey R Hopkins
Journal:  J Med Chem       Date:  2011-10-19       Impact factor: 7.446

2.  Computer-Based Visualization System for the Study of Deep Brain Structures Involved in Parkinson's Disease.

Authors:  Juan A Juanes; Pablo Ruisoto; José A Obeso; Alberto Prats; Joan San-Molina
Journal:  J Med Syst       Date:  2015-09-14       Impact factor: 4.460

Review 3.  Neuroimaging with magnetoencephalography: A dynamic view of brain pathophysiology.

Authors:  Tony W Wilson; Elizabeth Heinrichs-Graham; Amy L Proskovec; Timothy J McDermott
Journal:  Transl Res       Date:  2016-01-25       Impact factor: 7.012

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

5.  RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.

Authors:  Katelin E Ahlers-Dannen; Mackenzie M Spicer; Rory A Fisher
Journal:  Mol Pharmacol       Date:  2020-02-03       Impact factor: 4.436

6.  Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.

Authors:  Zili Luo; Katelin E Ahlers-Dannen; Mackenzie M Spicer; Jianqi Yang; Stephanie Alberico; Hanna E Stevens; Nandakumar S Narayanan; Rory A Fisher
Journal:  JCI Insight       Date:  2019-05-23

Review 7.  Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis.

Authors:  Ying-hui Chou; Patrick T Hickey; Mark Sundman; Allen W Song; Nan-kuei Chen
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

8.  Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities.

Authors:  Rodney C Samaco; Caleigh Mandel-Brehm; Hsiao-Tuan Chao; Christopher S Ward; Sharyl L Fyffe-Maricich; Jun Ren; Keith Hyland; Christina Thaller; Stephen M Maricich; Peter Humphreys; John J Greer; Alan Percy; Daniel G Glaze; Huda Y Zoghbi; Jeffrey L Neul
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

9.  Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.

Authors:  Markos Poulopoulos; Cheryl Waters
Journal:  Core Evid       Date:  2010-07-27

Review 10.  Prevalence and definition of drooling in Parkinson's disease: a systematic review.

Authors:  J G Kalf; B J M de Swart; G F Borm; B R Bloem; M Munneke
Journal:  J Neurol       Date:  2009-03-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.